Biopharma Boardroom speaks with Dr Anthony Bradley, Co-Founder and Chief Scientific Officer at Dalton, about how the company is bringing anti...
Northwestern Medicine, Chicago’s premier integrated academic health system, and OpenEvidence, a leading AI-powered medical search and clinical decisi...
Study published in Journal of Extracellular Vesicles validates platform for new class of liquid biopsy: multiomic disease biology of living cells from ...
GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced that it signed a Memorandum of Unders...
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new dr...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that...
Biopharma Boardroom speaks with Quentin Le Masne de Chermont, Head of Corporate Strategy and Business Development at Grünenthal Group, a...
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. (...
Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that the U.S. Food and Drug Admin...
- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1 - 100% of participants w...
In Cycle-1REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT-proBNP, a biomarker for heart failure, in patients with HFrEF o...
Biopharma Boardroom speaks with Nadia Aelbrecht, Vice President, Head of Infectious Disease at QIAGEN, about rapid diagnostics, antimicrobial...
Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral...
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete sy...
© 2026 Biopharma Boardroom. All Rights Reserved.
